Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05204355 · ClinicalTrials.gov registry record
MRI for Screening and Monitoring Scleroderma ILD
A clinical trial of Scleroderma, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT05204355 is a study of Scleroderma that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 25 participants, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05204355, a study of Scleroderma, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI
- DRUG Hyperpolarized Xe129
- DIAGNOSTIC_TEST HRCT
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2025-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05204355
The ClinicalTrials.gov registry entry for NCT05204355 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (94% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.
NCT05204355 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05204355 about?
NCT05204355 is a clinical study titled "MRI for Screening and Monitoring Scleroderma ILD". The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.
What is the current status of trial NCT05204355?
This trial is currently active not recruiting. The enrollment target is 25 participants. The study started on 2022-05-01. Estimated completion is 2025-10-31.
What conditions does trial NCT05204355 study?
This clinical trial studies the following conditions: Scleroderma.
What interventions are being tested in trial NCT05204355?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Hyperpolarized Xe129 (DRUG), HRCT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05204355?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05204355 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Scleroderma Registry & Repository at the Hospital for Special Surgery
RECRUITING
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.